Novartis Plans $450M Cost Cuts to Shoulder Diovan Patent Loss, Aliskiren Safety Concerns – Genetic Engineering News

The move is being made in light of both the impending loss of its U.S. Diovan (valsartan) patent in September and safety issues associated with combining the antihypertensive drug Rasilez/Tekturna (aliskiren) with angiotensin converting enzyme …

Leave a Reply

Your email address will not be published. Required fields are marked *